Provided by Tiger Trade Technology Pte. Ltd.

Immunome Inc.

26.12
-0.6900-2.57%
Post-market: 26.120.00000.00%19:30 EDT
Volume:784.12K
Turnover:20.62M
Market Cap:2.97B
PE:-10.51
High:26.99
Open:26.43
Low:26.10
Close:26.81
52wk High:30.06
52wk Low:8.93
Shares:113.58M
Float Shares:108.11M
Volume Ratio:1.06
T/O Rate:0.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4851
EPS(LYR):-2.4315
ROE:-64.03%
ROA:-37.78%
PB:5.65
PE(LYR):-10.74

Loading ...

Immunome Grants 86,500 Inducement Stock Options at $27.07 Per Share

Reuters
·
Yesterday

Immunome Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Yesterday

Immunome to Present at H.C. Wainwright Global Investment Conference

Reuters
·
Sep 02

Argenx's Myositis Data Strengthen Efgartigimod Outlook, Morgan Stanley Says

MT Newswires Live
·
Aug 18

Immunome (IMNM) Faces A Valuation Test Following Earnings And Shelf Registration

Simply Wall St.
·
Aug 18

argenx’s VYVGART Hytrulo hits Phase 3 myositis goal in high‑need IMNM and DM

TIPRANKS
·
Aug 17

argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

GlobeNewswire
·
Aug 17

Moleculin Biotech Expects Cash Position to Fund Operations into Q1 2027

Reuters
·
Aug 14

Replimune Q1 Net Loss Narrows as Expenses Decline

Reuters
·
Aug 14

Allarity Therapeutics Q2 Loss Narrows as Expenses Fall

Reuters
·
Aug 14

Genelux Posts Wider-than-Expected Q2 Loss on Higher R&D Expenses

Reuters
·
Aug 14

Inhibrx Biosciences Q2 Net Loss Widens on Higher Expenses

Reuters
·
Aug 14

NuCana Q2 Loss Narrows as Clinical Milestones Remain on Track

Reuters
·
Aug 14

Elicio Therapeutics Q2 Net Loss Narrows as R&D Expenses Fall

Reuters
·
Aug 14

PDS Biotechnology Q2 Net Loss Widens Slightly as Operating Costs Fall

Reuters
·
Aug 13

Pyxis Oncology Q2 Loss Widens on Increased Administrative Costs

Reuters
·
Aug 13

Immunome Director Isaac Barchas Reports Disposal of Common Shares Worth $2.18 Million

Reuters
·
Aug 13

Oncology Device Maker RenovoRx's Q2 Revenue Surges, Raises FY Outlook

Reuters
·
Aug 13

Immunome Price Target Raised to $35.00/Share from $31.00 by Wedbush

Dow Jones
·
Aug 13

Evercore ISI Remains a Buy on Immunome (IMNM)

TIPRANKS
·
Aug 12